Bangladesh’s maiden homegrown COVID-19 vaccine gets clearance for human trials
The Bangavax vaccine, developed by local pharma company Globe Biotech, recently received clearance from the Directorate General of Drug Administration under the Ministry of Health and Family Welfare after the relevant authorities reviewed all the documents on all the previous trials
Bangladesh’s first homegrown COVID-19 vaccine has obtained clearance for human trial in phase I.
The Bangavax vaccine, developed by local pharma company Globe Biotech, recently received clearance from the Directorate General of Drug Administration under the Ministry of Health and Family Welfare after the relevant authorities reviewed all the documents on all the previous trials.
“We’ve got the approval for phase-I clinical trial of Bangavax,” Mohammad Mohiuddin, a senior official at Globe Biotech, told reporters.
The trial will be conducted among 60 healthy volunteers at Bangabandhu Sheikh Mujib Medical University hospital in Dhaka, a news agency reported quoting Mohiuddin as saying.
In November last year, Bangavax, a single-dose COVID-19 vaccine, got ethical clearance from the Bangladesh Medical Research Council for a human trial on up to 64 healthy adult participants.
Globe Biotech applied for approval for a human trial on 1st November last year, saying its vaccine has yielded “good results” in trials on monkeys.
The vaccine can reportedly be stored at a temperature of four degrees Celsius for one month and of minus 20 degrees Celsius for up to six months.
Edits by EP News Bureau
- Advertisement -
